ResMed Inc.

NYSE:RMD 주식 리포트

시가총액: US$30.1b

ResMed 향후 성장

Future 기준 점검 2/6

ResMed (는) 각각 연간 7.5% 및 6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 8.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 28.8% 로 예상됩니다.

핵심 정보

7.5%

이익 성장률

8.51%

EPS 성장률

Medical Equipment 이익 성장16.4%
매출 성장률6.0%
향후 자기자본이익률28.75%
애널리스트 커버리지

Good

마지막 업데이트10 Jul 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha • Jun 29

ResMed: Fear-Driven Selloff Creates A Compelling Margin Of Safety Entry Point

Summary ResMed (RMD) exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpensive recurring costs, and a superior user experience. RMD dominates the sleep apnea market with a 62% share in a vast, under-penetrated addressable market with huge future growth potential. RMD’s financials are resilient, with consistent sales and earnings growth, no earnings misses in more than a decade, and a predictable business model. CMS exclusion and tariff exemptions remove two major near-term headwinds for ResMed's margins. My fair value estimate suggests a 12% margin of safety at current prices — rated Buy. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 26

RMD: Sleep Health Demand And GLP 1 Therapies Will Support Future Upside

Analysts have trimmed their fair value estimate for ResMed by $10 to $260.60. This reflects lower price targets driven by expectations of moderating revenue growth and profit margins, despite ongoing interest in sleep apnea demand trends.
분석 기사 • Jun 19

ResMed (RMD) Stock Could Be 30.3% Undervalued After Morgan Stanley Downgrade

Morgan Stanley’s downgrade of ResMed (RMD), citing limited near term profit margin growth and rising competitive risks from Philips and GLP-1 weight-loss drugs, has put fresh attention on how the stock’s story is changing. See our latest analysis for ResMed. At a share price of US$188.63, ResMed has seen its 30 day share price return fall 9.22% and its year to date share price return fall 22.95%, while the 1 year total shareholder return is down 24.08%. This suggests recent downside pressure...
내러티브 업데이트 • Jun 05

RMD: Sleep Health Partnerships And Acquisitions Will Support Long Term Upside

ResMed's updated analyst price target has shifted lower to $270.60 from $288.21, as analysts factor in revised fair value assumptions and a more conservative future P/E outlook, while maintaining steady expectations for revenue growth and profit margins. Analyst Commentary Recent Street research around ResMed has mixed implications for valuation and execution, with several firms trimming price targets while one major bank has started coverage with a positive stance.
새로운 내러티브 • May 18

GLP 1 Therapies And Sleep Apnea Links Will Drive Powerful Long Term Tailwinds

Catalysts About ResMed ResMed develops and sells sleep and respiratory care devices, masks and cloud-connected software that support treatment and monitoring in the home. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • May 01

GLP 1 Therapies And Margin Pressures Will Challenge Long Term Earnings Sustainability

Catalysts About ResMed ResMed develops and sells sleep and respiratory care devices, masks and cloud-connected software that support treatment in the home. What are the underlying business or industry changes driving this perspective?
내러티브 업데이트 • May 01

RMD: Distribution Expansion And Execution Discipline Will Drive Future Upside

ResMed's updated analyst price target has slipped by about $8 to reflect slightly more cautious assumptions on revenue growth, profit margins, discount rate and future P/E, with several firms trimming targets even as others maintain a constructive view. Analyst Commentary Recent Street research on ResMed has tilted more cautious on valuation, even as one major firm has initiated with a bullish stance.
내러티브 업데이트 • Apr 12

RMD: Distribution Expansion And Margin Strength Will Support Future Upside

ResMed's analyst price target has been nudged lower by about $0.33 as analysts balance a slightly higher discount rate with firmer revenue growth, profit margin assumptions, and modest target increases from several firms alongside a more recent $5 trim from Citi. Analyst Commentary Recent Street research around ResMed reflects a mix of optimism on the company’s execution and growth profile, alongside a more cautious stance on valuation and near term expectations.
내러티브 업데이트 • Mar 29

RMD: Higher Earnings Visibility And Margins Will Support Future Upside

Analysts have lifted the consolidated ResMed price target by $15, reflecting updated views on its long term growth, margin profile and P/E assumptions in light of recent research from Citi, RBC Capital, Stifel, KeyBanc and Baird. Analyst Commentary Recent Street research points to a cluster of higher price targets for ResMed, with different teams revisiting their assumptions around growth durability, margin structure and the P/E multiple they are willing to apply.
내러티브 업데이트 • Mar 14

RMD: AI Sleep Personalization And New Distribution Hub Will Support Upside

ResMed's analyst price target has edged lower by about $1 to $296.87, as analysts fine tune their models around slightly different fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, while keeping an overall constructive stance. This stance is reflected in a series of recent target increases across the Street.
내러티브 업데이트 • Feb 28

RMD: AI Sleep Therapy Personalization Will Support Long Term Upside

ResMed's analyst price target has moved higher by several dollars to reflect a modest adjustment to discount rate assumptions, while multiple firms have raised their targets by $3 to $15. Analysts point to supportive fundamentals for the updated view.
내러티브 업데이트 • Feb 14

RMD: AI Sleep Therapy Personalization And Buyback Will Support Long Term Upside

Our updated ResMed narrative reflects a modest lift in the implied analyst price target to about $297.47, with analysts pointing to slightly higher assumed revenue growth, a small improvement in profit margins, and a marginally lower future P/E multiple as key drivers of the change. Analyst Commentary Recent Street research shows a cluster of upward price target revisions for ResMed, with several firms lifting their targets by between $3 and $15.
내러티브 업데이트 • Jan 31

RMD: AI Therapy Personalization Will Support Sustained Long Term Upside Potential

Narrative Update on ResMed Analysts have lifted their price targets on ResMed, supporting a modest fair value adjustment to about $296.40 as they factor in updated expectations for growth, profitability, and a slightly lower future P/E assumption. Analyst Commentary Recent Street research on ResMed points to a cluster of price target increases, with several bullish analysts nudging their targets higher by incremental amounts.
내러티브 업데이트 • Oct 21

Analyst Commentary Highlights Margin Optimism as ResMed Faces Market Headwinds and Patent Challenge

Analysts have raised their price target for ResMed to $295 from $292, citing improved profit margin expectations and better anticipated gross margin expansion. This comes despite concerns over slower market growth dynamics.
분석 기사 • Sep 06

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Jul 29

Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Key Insights ResMed's estimated fair value is US$302 based on 2 Stage Free Cash Flow to Equity Current share price of...
Seeking Alpha • Apr 24

ResMed: Cornering The Market In Sleep Solutions

Summary ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, enhancing its product portfolio, customer experience, and expanding into new markets, justifying its premium share price. Concerns about GLP-1 drugs reducing ResMed's market are countered by data suggesting increased overall health engagement, boosting interest in sleep health solutions. ResMed's consistent innovation and market leadership make it a highly attractive investment, despite its shares already trading at a substantial premium. Read the full article on Seeking Alpha
Seeking Alpha • Feb 10

Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions

Summary ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Watch, underscores a significant growth opportunity, with millions still undiagnosed and untreated globally. Concerns over GLP-1 drugs reducing CPAP demand have diminished. Despite an 8.3% stock dip post-earnings, ResMed remains undervalued, trading below its 5-year average P/E ratio, with strong growth prospects supported by innovation and macro trends. Read the full article on Seeking Alpha
Seeking Alpha • Feb 01

ResMed: Snoozers Can Be Winners

Summary I believe ResMed is currently overvalued relative to its intrinsic value, making it a good time for investors to take some profits. RMD’s growth has been driven by COVID-19, Philips' product recall, and acquisitions, with a projected growth rate of 9% per year until FY2030. The company's competitive position is strong, with a high ROIC and increasing operating margins, particularly in the SaaS division. Despite the potential impact of GLP-1 drugs, RMD’s demand remains robust, and the company is well-managed with market-leading products. Read the full article on Seeking Alpha
Seeking Alpha • Jan 24

ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)

Summary ResMed's share price has outperformed the S&P 500 by ~35% since my October 2023 Buy rating. The stock’s outperformance has been driven by a combination of earnings growth and multiple expansion. Operating conditions for ResMed remain positive, but taking a longer-term perspective, investors should be mindful of downside risks related to GLP-1 drugs and the eventual return of Respironics. ResMed’s valuation now looks slightly stretched, however a supportive near-term outlook is sufficient to justify a Hold rating. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:RMD - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
6/30/20296,6741,8141,7761,9402
6/30/20286,3851,8301,7711,94615
6/30/20275,9691,6481,7051,82816
6/30/20265,6501,5481,6301,75814
3/31/20265,5381,5201,7361,890N/A
12/31/20255,3981,4861,7771,914N/A
9/30/20255,2571,4381,7571,883N/A
6/30/20255,1461,4011,6511,752N/A
3/31/20255,0221,3131,5601,653N/A
12/31/20244,9271,2491,3841,476N/A
9/30/20244,8071,1131,3471,441N/A
6/30/20244,6851,0211,2861,401N/A
3/31/20244,5849581,0711,199N/A
12/31/20234,5048909441,079N/A
9/30/20234,375907792935N/A
6/30/20234,223898559693N/A
3/31/20234,016863408535N/A
12/31/20223,763809222370N/A
9/30/20223,624786305461N/A
6/30/20223,578779195351N/A
3/31/20223,539779344498N/A
12/31/20213,444522446577N/A
9/30/20213,349500397527N/A
6/30/20213,197475620737N/A
3/31/20213,091457733840N/A
12/31/20203,092699774884N/A
9/30/20203,028680684784N/A
6/30/20202,957622696802N/A
3/31/20202,892513505614N/A
12/31/20192,784455N/A514N/A
9/30/20192,699419N/A573N/A
6/30/20192,607405N/A459N/A
3/31/20192,525446N/A447N/A
12/31/20182,455450N/A456N/A
9/30/20182,405335N/A459N/A
6/30/20182,340316N/A505N/A
3/31/20182,273307N/A516N/A
12/31/20172,196285N/A434N/A
9/30/20172,125352N/A422N/A
6/30/20172,067342N/A414N/A
3/31/20172,029324N/A417N/A
12/31/20161,968327N/A474N/A
9/30/20161,893346N/A510N/A
6/30/20161,839352N/A548N/A
3/31/20161,773357N/A505N/A
12/31/20151,742357N/A471N/A
9/30/20151,710353N/A421N/A

애널리스트 향후 성장 전망

수입 대 저축률: RMD 의 연간 예상 수익 증가율(7.5%)이 saving rate(3.5%)보다 높습니다.

수익 vs 시장: RMD 의 연간 수익(7.5%)이 US 시장(18.2%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: RMD 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: RMD 의 수익(연간 6%)이 US 시장(연간 12.9%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: RMD 의 수익(연간 6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: RMD의 자본 수익률은 3년 후 28.8%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/07/10 23:54
종가2026/07/10 00:00
수익2026/03/31
연간 수익2025/06/30

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

ResMed Inc.는 47명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
David RescottBaird
Michael PolarkBaird
Matthew TaylorBarclays